Project Grant R01HL188318
Award Date 8/4/26
Completion Date 4/30/30
Dollars Obligated $787K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $1,574,578 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel targeted modified mRNA delivery strategies for donation after circulatory death (DCD) heart transplantation. The research addresses primary graft dysfunction (PGD), an ischemia-reperfusion injury occurring in approximately 35 percent of heart transplants and driven by hyper-inflammatory responses involving...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $1.102 million in funding under the Cardiovascular Diseases Research program (CFDA 93.837) on July 1, 2026, for a Project Grant (R35HL182842) supporting research into the regulation of ubiquitin E3 ligases and innate immunity in acute respiratory distress syndrome (ARDS). The research investigates immunosuppressive F-box proteins that degrade key substrates essential for host innate immunity and cytoprotective...
- The National Heart, Lung, and Blood Institute awarded New York University a Project Grant of $847,373 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The project will use national organ transplant registry data, including structured clinical data and unstructured narratives describing donor chest imaging findings, to improve evidence for lung offer decisions in transplantation. Large language models will be trained to extract structured data elements from...
- The National Heart, Lung, and Blood Institute awarded The Washington University Office of Sponsored Research Services $388,750 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of recipient-derived B cells in regulating ischemia reperfusion injury and its link to alloimmune responses after lung transplantation. The research addresses mechanisms of primary graft dysfunction and chronic lung allograft dysfunction following lung...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $156,080 on February 19, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research into the role of NCOA4-mediated ferritinophagy in ozone-induced pulmonary ferroptosis. The research investigates mechanisms by which ground-level ozone exposure induces pulmonary injury and inflammation. Preliminary data indicate that acute ozone inhalation increases lung tissue gene expression of...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $729,984 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 22, 2026. The award funds development of a three-dimensional real-time cardiovascular magnetic resonance imaging (3D RT CMR) reconstruction framework for imaging patients with cardiac arrhythmias. The proposed unsupervised reconstruction method, called Generative Prior with Multi-Dynamic Modeling (GEMM), enables highly accelerated 3D RT...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $1,741,543 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung injury in pediatric hematopoietic cell transplant recipients. The research examines molecular mechanisms of pulmonary toxicity in pediatric HCT recipients, who experience lung injury in up to 40% of cases with mortality rates of 40% when requiring...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $768,600 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the lung macrophage efflux system in the pathogenesis of Mycobacterium tuberculosis. The research aims to identify host-directed therapeutic targets for tuberculosis treatment. The work focuses on two objectives: defining the role of the multidrug resistance transporter MDR1 in M. tuberculosis survival...
- The National Heart, Lung, and Blood Institute awarded The Washington University $169,140 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support immuno-metabolic research into chronic rejection after lung transplant. The funding supports investigation of the mechanistic drivers of bronchiolitis obliterans syndrome (BOS), a form of chronic rejection that is the major cause of death one year after lung transplant. The principal investigator, a lung transplant...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $236,250 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026, as a Project Grant (R21HL184279). The award funds secondary analysis of right heart catheterization data within the PVDOMICS cohort to phenotype right ventricular dysfunction across the pulmonary hypertension spectrum. The research will quantify right ventricular function including contractility, afterload, diastolic...